Introduction
The cancer stem cell model predicts that the entire tumor mass emerges from a small proportion of proliferating cells with self-renewal capacity. Early evidence has shown that a small fraction of multiple myeloma (MM) cells is capable of colony formation originating from a single malignant cell in both mice and humans (1) . Previous work has identified CD19þ B lymphocytes that express the corresponding light chain of myeloma plasma cells in the peripheral blood of patients with myeloma referred to as clonotypic B cells (2) . The clonal relationship among B cells and malignant plasma cells has also been confirmed by molecular methods (3) . Clonotypic B cells in myeloma bone marrow have been described in few reports, although not studied in depth (3, 4) .
Attempts have been made to study the relationship between clonotypic CD19þ B cells and MM cancer stem cell. Putative MM cancer stem cell has been debated in the literature as being the phenotype of a preswitch and/or a postswitch MM B cell. Evidence for preswitch B-cell progenitors with stem cell-like properties has been described in CD34þ/CD19À cell subsets, which have resulted in xenograft myeloma in immuno-compromised hosts (5) . An immature B-cell subset characterized for the coexpression of CD19þ/CD34þ/CD11bþ in peripheral blood has been shown to have a clonal relation with the original patient's malignant plasma cells (6) , although this has not been consistently identified (7) . The existence of a B preswitch isotype species clonally related to myeloma has also been identified in bone marrow (3) . B cells expressing clonotypic cytoplasmic immunoglobulin (Ig) M (cIgM) cells (preswitch) in patients with myeloma have been shown to be correlated with poor patient outcome (8) ; however, additional work from the same group has shown that myeloma may originate from a single class switch event in cIgM cells with ongoing mutations in the postswitch progeny, suggesting that cIgM cells may not be involved in disease progression (9) . It has been also suggested that memory B cells represent a clonotypic remnant that is only partially transformed and may not be involved in maintaining tumor, as B cells express early myeloma-specific oncogenes but they lack late oncogene K-RAS mutations (10) .
DNA sequencing revealed somatically hypermutated but homogeneous Ig heavy-chain genes, suggesting that, in myeloma, clonal proliferation may occur in cells that have already passed through phases of somatic hypermutation (11) . Clonotypic B cells have been identified in the CD19þ/CD38þ/CD56þ/monotypic Ig light-chain blood compartment, characteristic of late-stage B or preplasma cells (12) (13) (14) . Malignant CD19À plasma cells have been reported as aneuploid, whereas cells expressing CD19 were diploid, supporting the concept that myeloma is a disease process mediated by a self-replicating late compartment of B-cell ontogeny (15) . A long-term proliferating compartment in myeloma has been described in cells lacking expression of syndecan-1 and CD34 (CD138À/CD34À), characterized by a CD19þ/CD27þ/CD20þ phenotype, suggesting that myeloma may arise from the self-renewing memory B-cell compartment (4, 16) .
Controversy arises as both cell subsets, B cells (CD138À/ CD19þ) and plasma cells (CD38þ/CD45À), have been shown to reproduce myeloma in xenograft models (4, 16, 17) . Mature plasma cells have been shown to have proliferative and stem cell-like properties. Plasma cells include a subset of proliferating cells present within CD45 bright cells; this subset has been postulated to be a growth fraction in myeloma (18) . CD138þ cells have been shown to contain a stem cell-like side population with high-proliferation index that is sensitive to lenalidomide (19) . Clonogenicity of CD138þ cells has been shown with dendritic cells in coculture support (20) .
The clinical significance of monoclonal CD19þ cells remains to be determined. Patients with myeloma have been reported to have increased numbers of circulating B cells, with numbers significantly increased after relapse (12, 21) . In contrast, CD19þ blood myeloma cells were not significantly different from median levels shown in normal controls, although CD19þ cell levels convened an improved survival (22) . CD19þ cells are not eliminated by any conventional or high-dose chemotherapy regimen (12, 21, 23) , although they are undetectable after allogeneic transplant in 1 patient (23) .
In this study, we purified light chain-restricted (LCR) CD19þ B cells using multiparameter flow cytometry and cell sorting and confirmed that bone marrow B cells from patients with myeloma are clonally related to malignant plasma cells. Herein, we showed that marrow CD19þ/ CD34þ and more differentiated CD19þ/CD34À B-cell samples exhibited a stem cell-like aldehyde dehydrogenase-positive (ALDHþ) phenotype, which were able to grow colonies in colony formation assay (CFC), suggesting that an antigen-independent B-cell maturation stage may be involved in disease origin. We confirmed chemoresistance of B-cell progenitors to conventional myeloma agents and showed that panobinostat, a novel histone deacetylase inhibitor, exhibits activity against progenitor and mature plasma cells.
Materials and Methods

Patient specimens
Human bone marrow and peripheral blood were obtained, with Institutional Review Board approval, by aspiration from the posterior iliac crest of patients with MM either at the time of diagnosis or at the time of clinical evidence of disease relapse. All human participants provided written informed consent. Bone marrow mononuclear cells were isolated by Ficoll-Hypaque gradient purification (Mediatech-Cellgro) and kept in Minimum Essential Media (MEMa; Invitrogen) supplemented with 20% FBS (Omega Scientific) and 1% penicillin/streptomycin (Invitrogen) at a concentration of 2 Â 10 6 cells/mL until use within 18 hours from bone marrow collection. The HS5 human cell line was obtained from American Type Culture Collection and maintained in RPMI 1640 (Invitrogen) supplemented with 10% FBS. HS5 cells were passaged for less than 3 months before renewal from frozen early-passage stocks. Cells were regularly screened for Mycoplasma using a MycoAlert Mycoplasma Detection kit (Lonza).
Compounds
Bortezomib (Fisher Scientific) and panobinostat (LBH 589; Novartis) were reconstituted in dimethyl sulfoxide (DMSO) and stored at À20 C until use. Bortezomib was used at 10 nmol/L for 48 hours. Panobinostat was used at 100 nmol/L for 24 hours. Melphalan (Sigma/M2011) was
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reconstituted in acid-ethanol and stored at À80 C until use (33 mmol/L). Melphalan was used at 25 mmol/L for 24 hours. Apoptotic-induced cell death was determined by flow cytometry using annexin V-PE and 7-amino actinomycin-D. The percentage-specific cell death was calculated as follows: [(experimental apoptosis À spontaneous apoptosis)/(100 À spontaneous apoptosis)] Â 100.
Flow cytometric acquisition and sorting
Characterization of the progenitor population was conducted using a series of multiple color antibody panels containing up to 7 colors. The panels included (i) CD138-APC, CD14-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue; (ii) CD138-APC, CD27-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue, CD20-PerCPCy5.5; (iii) CD138-APC, CD56-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue; (iv) CD138-APC, CD34-FITC, kappa-PE or lambda-PE, CD45-PECy7, CD19-PacBlue; (v) CD138-APC, CD38-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue; (vi) CD138-APC, CD14-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue, CD117-PerCP-Cy5.5; and (vii) CD138-APC, Notch-1-biotin, streptavidin-FITC, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue; CD138-APC, survivin-AF488, kappa-PE or lambda-PE, CD34-PECy7, CD19-PacBlue. All antibodies were obtained from BD Biosciences except CD19-PacBlue (Invitrogen), Notch-1-biotin (eBiosciences), and survivin-AF488 (Cell Signaling Technologies). A minimum of 3 Â 10 5 cells were acquired. All panels included a viability marker, Live/Dead Fixable Yellow Dead Cell Stain kit (Invitrogen). All analyses were conducted using Flowjo software (Treestar). Samples were acquired on a LSRII (BD) equipped with 488, 532, 633, and 405 nm excitation lasers.
To determine ALDH activity of bone marrow mononuclear cells, we used Aldefluor (Stem Cell Technologies), as per manufacturer's instructions. Activated Aldefluor reagent was added to freshly isolated cells; 30 minutes later, cells were transferred to a tube containing the inhibitor, diethylaminobenzaldehyde (DEAB). Samples were incubated at 37 C for 1 hour and subsequently stained with CD138-APC, kappa-PE or lambda-PE, CD34-PE-Cy7 (BD Biosciences), and CD19-Pacific Blue (Invitrogen). A minimum of 1 Â 10 6 cells were acquired for ALDH analyses. For sorting, freshly isolated bone marrow mononuclear cells were stained at 10 Â 10 6 cells/mL with CD138-APC, CD14-FITC, kappa-PE or lambda-PE, CD34-PE-Cy7, CD19-Pacific Blue, and a viability marker, Live/Dead Fixable Yellow Dead Cell Stain kit (Invitrogen). Samples were acquired and sorted using a FACSAria-SORP (BD) equipped with 488, 640, 407, 561, and 355 nm excitation lasers. To ensure that only live single cells were collected, we used forward scatter (FSC)-width (W) versus FSC-height (H) and side-scattered (SSC)-W versus SSC-H plots to exclude doublets or cell aggregates. Dead cells were excluded by gating the cells negative for the viability marker. Cells were then gated on CD14-negative cells to exclude monocytes. Finally, cells positive for the light chain of the patient were then gated, and clonotypic cells were sorted into the following populations: (i) LCR CD138þ, (ii) LCR CD138À CD19þCD34À, (iii) LCR CD138ÀCD19þCD34þ, (iv) LC-CD138ÀCD19ÀCD34þ, (v) LCR CD138ÀCD19þ CD27þ, and (vi) LCR CD138ÀCD19þCD27À. We recovered 4 Â 10 5 to 2 Â 10 6 cells using the above phenotype restrictions, with purity of the sorted populations shown to be greater than 95% (Supplementary Fig. S1 ). For LCR CD138ÀCD19þCD34þ cells, purity was not checked after sorting because a low number of cells were recovered.
Immunoglobulin gene rearrangement detection
Whole genomic DNA was extracted and amplified from 3 Â 10 4 to 1 Â 10 5 sorted subpopulations using the REPLI-g Mini kit (Qiagen). Sorting gating strategy was first based on light chain expression (Kappa or Lamba) and sorted on the basis of phenotype as follows: A ¼ CD138þ/light chainþ and B ¼ CD138À/CD19þ/light chainþ. To determine Ig heavy chain rearrangements, the amplified genomic DNA was further amplified by PCR using fluorescently labeled primers from the IGH Gene Rearrangement Assay Kit (InVivoscribe Technologies) targeting the joining region (J) and the 3 conserved framework regions between V and J within the IGH gene, as per manufacturer's instructions. To determine immunoglobulin kappa/lambda light-chain gene rearrangement, fluorescently labeled primers targeting Vk -Jk and Vk -Kde for kappa and conserved regions within Vl1-3 and Jl1-3 regions that flank the complementarity determining region 3 for lambda were used (InVivoscribe). No template and amplification controls were run in each test. The resulting PCR products were separated and detected by capillary electrophoresis on the ABI 3130 Â l, using GeneMapper 4.0 software (Applied Biosystems).
Immunoglobulin gene rearrangement sequencing
The resulting PCR products, as described above, were run in a 2% agarose gel. Clonal bands within the valid assay range were cut and gel extracted using the MinElute Kit (Qiagen) and sequenced on an Applied Biosystems 3130ÂL genetic analysis system using the primers provided in the IGH Somatic Hypermutation Kit. Sequences were analyzed using VBASE and ClustalW2 multiple sequence alignment.
Colony formation assays
Each flow cytometric-sorted population was resuspended in IMEM (Mediatech-CellGro) þ 2% FBS (Stem Cell Technologies, catalog #07700) and plated in triplicate in 35 mm 2 dishes with methylcellulose containing 5% phytohemagglutinin (PHA; Methocult H4533, Stem Cell Technologies) as per the manufacturer's instructions at a concentration of 1,000 cells/mL for CD34þ cells and at least 100,000 cells/mL for other populations. Conditioned medium from HS5 cells was added where noted, in place of IMEM þ 2% FBS. For cultures containing cytokines, IL-2 (50 U/mL), IL-6 (10 ng/mL), IL-10 (50 ng/mL), IL-15 (20 ng/mL), and IL-21 (100 ng/mL; R&D Systems) were added. Cultures were grown at 37 C to 5% CO 2 with a water bath, and colony growth was assessed 14 to 21 days later.
Colony morphology was assessed by the Wright-Giemsa staining method using the Hema 3 Stat Pack (Fisher Scientific) in cytospins slides examined with immunofluorescence microscopy or flow cytometry.
Results
Clonotypic B cells in multiple myeloma bone marrow
Clonotypic B-cell progenitors may contain the putative myeloma cancer stem cell, and represent a malignant, drugresistant compartment responsible for disease relapse. Characterization of this population(s) is necessary to improve our management of the disease and patient outcomes. We evaluated marrow cells from 58 patients with myeloma for expression of plasma cell and B-cell progenitor surface markers by multicolor flow cytometry and identified distinctive marrow populations based on CD34, CD19, and syndecan-1 (CD138) expression. Plasma cells were shown to be positive for CD138 and negative for CD34 and CD19. Among cells negative for CD138, hematopoietic stem cells (HSC) or multipotent progenitors are CD34þ/CD19À, and B cells progenitors encompass CD34þ/CD19þ or CD34À/CD19þ subpopulations (24, 25) . A minority of the CD19þ marrow cells exhibited a CD34þ phenotype, but most had a differentiated, CD34À, B-cell phenotype. To exclude monocyte contamination, we applied a strict, low SSC gate on CD138À cells ( Supplementary Fig. S1 ). In blood of patients with myeloma (n ¼ 8), we detected very low numbers of circulating plasma cells and a few differentiated CD19þ B cells, but no CD34þ/CD19þ cells (Fig. 1A) .
To assess for expression of the myeloma clonotype in marrow B cells, we tested initial patients (n ¼ 8) for kappa or lambda light-chain expression using an intracytoplasmic and a surface staining protocol. As expected, cytoplasmic stain was brighter than the surface stain, but percentages of light-chain cells positive by either assay were comparable (data not shown). No light-chain expression was detected in the CD34þ/CD19À or the CD34/CD19/CD138-triple negative marrow cells (Fig. 1A) . Malignant plasma cells expressed either kappa or lambda light chain. Although the CD19þ light chain stain was perhaps skewed in the same direction as the malignant plasma cells, all patients who were tested also had some CD19þ cells that expressed the opposite light chain (Fig. 1A) .
To determine whether marrow CD19þ cells that expressed a surface light chain identical to the plasma cells were clonally related to the myeloma clone, we tested flowsorted LCR B cells and plasma cells for the Ig heavy-and light-chain gene clonal rearrangements. Fluorescently labeled PCR products were tested by capillary gel electrophoresis; results showed a clonal population of cells yielding the same prominent amplified product within the expected size in both LCR B-cell progenitors and plasma cells (Fig. 1B) . Furthermore, both myeloma populations showed identical sequences for IGH somatic hypermutation, confirming the same malignant clone ( Supplementary  Fig. S2 ). Therefore, we focused on LCR B cells as they are clonally related to myeloma with the understanding that a proportion of these cells correspond to normal B-cell precursors.
It has been postulated that B-cell numbers are indicative of myeloma burden. In our study, we observed a very low proportion of LCR B cells in the marrow of patients with newly diagnosed (0.7 AE 0.5%; n ¼ 29) or patients with clinical relapse (0.5 AE 0.4%; n ¼ 29; Fig. 1C ) as previously shown in blood of patients with myeloma (22) .
We next assessed the kappa/lambda light-chain ratio of bone marrow CD138À/CD19þ B cells progenitors. As shown in Fig. 1D , in newly diagnosed patients, the mean ratio was 1.5 AE 0.6 and 1.02 AE 0.4 for kappa-and lambdarestricted patients, respectively. For relapsed patients, the results were similar (1.25 AE 0.5 for kappa and 1.3 AE 0.5 for lambda patients) and comparable to those shown in healthy donors. Based on these results, commonly used criteria for plasma cell (CD138þ) LC restriction (kappa LCR > 4.0 or lambda LCR < 0.5) may not be applicable to malignant B-cell progenitors.
Stem-like phenotype of clonotypic B-cell progenitors in multiple myeloma bone marrow
We first evaluated the phenotype of LCR CD19þ cells with emphasis on known B-cell progenitors and malignant plasma cell antigens, as presented in Table 1 (n ¼ 7). LCR CD34þ/CD19À were characterized by aberrant CD27 and CD20 expression and low levels of CD10 and CD56 markers. ALDH is one of a family of enzymes involved in several detoxifying pathways. Elevated ALDH expression has recently been used to identify a rare stem cell-like population in normal hematopoietic cells and in several tumor types, including leukemia, brain, colon, and breast cancer (26) (27) (28) (29) and in MM (16) . To determine whether myeloma bone marrow B progenitors contain a high ALDHexpressing stem cell-like population, we used the aldefluor reagent to test for ALDH activity. For each of the tested patients (n ¼ 8), a control sample was run containing a population of cells with fluorescence that is inhibited by the ALDH inhibitor DEAB. High ALDH activity was detected in a mean of 3.05% (0.09%-7.26%) and 2.94% (0.01%-6.9%) of LCR CD34þ/CD19þ and CD34À/CD19þ B cells, respectively, and in 8% (1.3%-15.3%) of CD34þ/CD19À hematopoietic progenitors. ALDH activity was diminished in CD34þ/CD19À progenitor cells from patients with myeloma and increased in myeloma LCRCD19þ/CD34þ or CD34À cells when compared with healthy subjects subpopulations ( Fig. 2A) .
We investigated Notch and survivin expression in LCR B cells as they are involved in HSC and/or malignant plasma cell survival. B-cell progenitors were characterized by high Notch-1 (90 AE 6%) and survivin (97 AE 2%) expression levels (Fig. 2B) in all patient samples analyzed (n ¼ 4) . Expression of Notch-1 and survivin in healthy bone marrow (n ¼ 3) was more than 90% in CD19À/CD34þ, CD19þ progenitors, and CD138þ cells (data not shown). In addition, we examined tyrosine-protein kinase c-Kit (CD117) expression levels in B progenitor cells. Historically, normal B-cell progenitors in humans are CD117 negative, findings confirmed in healthy bone marrow (data not shown). B-cell malignancies are characterized as having either negative (B-ALL, lymphoid crisis chronic myelogenous leukemia) or positive CD117 expression (myeloma, B-diffuse large-cell lymphoma; refs. 30, 31). We identified aberrant CD117 expression (n ¼ 3) in a mean of 20.5% (range 11-25) of CD19þ/CD34þ cells (n ¼ 3), in 7.8% (range 2.8%-17%) of CD19þ/CD34À B cells (n ¼ 7), and in 4.2% (range 0-15) of CD138þ cells (n ¼ 6; Fig. 2B ). Our results showed that CD19 progenitors coexpressed c-Kit in all samples, whereas only 2/6 patient samples coexpressed CD117/CD138. The functional role of Notch, survivin, and c-Kit on clonotypic B-cell progenitors in myeloma remains to be determined.
Colony formation assay of clonotypic B-cell progenitors in multiple myeloma
To test the hypothesis that B cells of patients with myeloma are enriched for CFC, we isolated marrow cells by flow sorting. During the initial experiments, the gating strategy was selected to compare colony formation in methylcellulose by CD34 and light-chain-restricted CD19þ cells (gate i: kappa or lambda restriction as plasma cell of each patient; gate ii: CD138À/CD19þ or CD138þ/CD19À). The sorting purity was greater than 98% in the majority of samples, excluding the possibility of contaminating cells (Supplementary Fig. S3 ). Subpopulations were grown for 14 days in CFCs on methylcellulose, supplemented with 5% lymphocyte-conditioned medium to favor lymphoid differentiation. CD34 cells from patients with myeloma bone marrow (n ¼ 5) were highly efficient, requiring 1,000 cells/plate to successfully grow colonies (Fig. 3A) . On the other hand, a minimum of 100,000 cells/plate were needed for colony formation derived from B cells with a colony efficiency estimated in 1 in 25,000 cells. CD138þ were unable to form colonies (n ¼ 8) despite increased input number (300,000-1,000,000 cells/plate); however, a few isolated cells persisted in culture. Cells harvested on day 14 are lympho-plasmacytoid (Fig. 3A) . As shown in Fig. 3B , a small fraction of CD34þ/CD19À cells are able to terminally differentiate into CD138þ cells (8 AE 2%); as opposed to LCR CD19þ B cells that differentiated into CD138þ cells (80 AE 5%). Colony formation of sorted CD34þ/CD19þ and CD34À/CD19þ B cells was tested in 3 patients with myeloma, with both cell subsets able to grow colonies. Furthermore, B cells, regardless of CD27 expression, successfully grew colonies. Data collected from these studies are shown in Fig. 3C . In summary, LCR B-cell progenitors in myeloma are able to grow colonies and differentiate into mature Interactions of hematopoietic progenitors and clonotypic B-cell progenitors in multiple myeloma with stroma-conditioned medium It has been well established that the tumor microenvironment creates a protective niche that supports myeloma growth (32) . In addition, stroma secretes multiple cytokines that support proliferation and differentiation of HSC and committed progenitors. Flow sorted CD34þ/CD19À cells from patients with myeloma were grown in methylcellulose supplemented with conditioned medium harvested from HS5 stroma grown for 48 hours (stroma-CM). CFC potential was compared using cytokines known to support plasmablast differentiation (33) . Colony efficiency was slightly improved using either stroma-CM or a combination of recombinant human-IL-2, IL-6, IL-10, IL-15, and IL-21. Similar results were obtained when either IL-15 or IL-21 was omitted from the cytokine cocktail (data not shown). Cells harvested from day 14 colonies are CD19þ (35%-50%), and very few terminally differentiated into CD138þ cells (3%-10%; Fig. 4A ). We next tested whether CFC efficiency of LCR CD19þ cells could be enriched in the presence of stroma-CM. Stroma-CM significantly improved colony number (3-fold) and size of each individual colony with an estimated colony efficiency of 1:10,000 cells (Fig. 4B) .
Apoptosis resistance of clonotypic B-cell progenitors in multiple myeloma bone marrow
We next isolated bone marrow cells by flow sorting to test chemosensitivity of LCR CD19þ cells in patients with myeloma. B cells exhibit relative resistance to melphalan, compared with plasma cells, as determined by annexin V/7-AAD staining (n ¼ 3; Fig. 5A ). B cells were less sensitive to apoptosis mediated by bortezomib (n ¼ 4; Fig. 5B ). Lenalidomide did not target LCR CD19þ cells (Fig. 5C ). We next tested the role of a hydroxamic acid-derived histone deacetylase inhibitor (LBH589, panobinostat), which has been shown to induce in vitro apoptosis in myeloma plasma cells (34) and acute lymphocytic lymphoblasts (35) . Panobinostat (100 nmol/L for 24 hours) activity against B-cell progenitors in all treated patients (n ¼ 5) was comparable to CD138þ cells (Fig. 5D) .
Discussion
Within the heterogenic cancer cell population, it is hypothesized that only a small subset of neoplastic cells is capable of extensive proliferation and differentiation leading to tumor development. In myeloma, the self-renewal compartment has been described within early B clonotypic lymphocytes or in memory B cells with the caveat that even CD34þ/CD19À(5) and mature CD138þ/CD38þ/CD45À have been shown to reproduce myeloma in xenograft models (17) . In our study, we provide evidence of the existence of clonotypic LCR B cells, confirmed by molecular studies, in bone marrow from a large series of adult patients, in agreement with previous reports (3, 36, 37) . Our analyses of discrete stages of B-cell differentiation by antigen expression patterns in myeloma paralleled normal B-cell development, with a few possible exceptions. Based on combined assessment of the CD19 and CD34 antigens, we showed the existence of clearly defined populations among LCR B cells. Both CD34þ/CD19þ and CD34À/CD19þ expressed light chain in all tested patients, suggesting aberrant light-chain processing in myeloma clone and/or aberrant expression of CD34 in mature CD19þ cells. If one assumes CD34þ/CD19þ as a more undifferentiated population, the relative number of B-cell subsets increased from more immature cells to more differentiated B cells, indicating that malignant B-cell differentiation parallels normal B-cell development. Multiparameter flow cytometry provides a powerful tool to elucidate different stages of B-cell development. In our study, we used a very strict gate criterion to exclude CD14þ cells, thus avoiding monocyte contamination because of nonspecific coating of M-protein to monocyte cell surfaces that is not completely washed off during specimen processing and/or unspecific binding of monoclonal antibodies, as previously described (38) . Our gating strategy, however, excluded myeloma monocytoid B cells characterized by a higher SSC/FSC, which are detected with specific anti-CD19 monoclonal antibody, thus explaining differences in results versus a previous report that used less stringent criteria (39) .
The overall number of CD19þ B cells in patients with myeloma is comparable to that shown in healthy individuals (40) . Clonotypic B-cell compartment size in patients with newly diagnosed or in patients with myeloma with clinical evidence of relapse remains constant, as previously shown in blood (22) . CD34þ/CD19þ cells were not detected in circulation, suggesting that these cells reside in the marrow niche. CD34þ/CD19þ expressed the TNF receptor CD27, expressed in normal memory B cells, and to a lesser extent CD20, denoting possible differentiation and/ or aberrant expression. CD27 has been reported to be expressed in progenitor B cells in other B-cell malignancies; however, its role in malignant growth remains to be defined (41, 42) . Work by Sanz and colleagues (24) suggested a dual B-cell development pathway where pro-B cells (CD34þ/ CD19þ/CD10þ) are preceded by either a pre-pro B-cell (CD34þ/CD19þ/CD10À) or a early B-cell/common lymphoid progenitor (CD34þ/CD19À/CD10þ) and formerly described in B-cell acute lymphocytic leukemia (43) . In MM B progenitors, we identified both CD10-negative and -positive subpopulations within CD34þ/CD19þ cells, potentially mimicking 2 distinct pathways. Stroma coculture differentiation studies could help to track the order of emergence of B-cell differentiation stages in MM.
To study "stemness" of LCR B cells, we assessed stem celllike phenotype and/or evaluated stem cell function by ALDH enzymatic activity and carried out in CFC assays. versus that shown in healthy donors, and CFC assays showed activity in all stages of B-cell differentiation in myeloma. In addition, hematopoietic stroma-derived cytokines support CFC growth of malignant B progenitors (44) . In summary, these finding suggest that a subset of marrow CD19þ/CD34þ cells and CD19þ/CD34À B cells in myeloma are enriched for cells with a cancer stem cell-like phenotype and/or function.
The cancer stem cell hypothesis postulates that this compartment is intrinsically more resistant to therapy than other tumor cells, constituting a minimal residual disease reservoir responsible for disease relapse. Successful therapy must therefore eliminate these cells, which is hampered by their high resistance to commonly used treatment modalities. In our study, we showed that LCR B cells are relatively resistant to agents commonly used to target CD138þ cells (melphalan, bortezomib, and lenalidomide) as previously shown (4, 16) . Panobinostat has been shown to be a potent growth inhibitor against resistant B lymphoblast-promoting histone hyperacetylation and cell growth gene regulation (35) . Ongoing panobinostat clinical trials have reported encouraging results in myeloma (45, 46) . In this study, we provide information suggesting a potential role of panobinostat to target clonotypic B cells. Strategies to optimize panobinostat-induced apoptosis in synergy with other drugs remain to be explored.
The clinical relevance of targeting cancer stem cell-associated surface markers has been previously shown (47) . CD117 seems to be aberrantly expressed in LCR B cells compared with normal B-cell progenitors. We hypothesize that, whereas c-Kit expression is preserved in clonotypic B-cell progenitors as they differentiate into mature malignant plasma cells, its expression is lost on the majority of patients with myeloma. Further studies in a larger series of patients are necessary to confirm these results and more importantly to explore both the functional role of c-Kit and the clinical utility of novel tyrosine kinase inhibitors. Treatment of patients with anti-CD20 antibody failed to achieve clinical response (39, 48) , suggesting the existence of myeloma CFC progenitors that are CD20 negative, as we have shown. Notch and survivin are expressed in all B-cell development stages. Novel treatment strategies with monoclonal antibodies, inhibitors, and/or vaccines to target these surface proteins should be explored before drawing any conclusions on the functional role of these molecules on myeloma B-cell progenitors (49, 50) .
Cancer chemotherapy is deemed successful if it reduces tumor burden and induces apoptosis of "cancer cells." The challenge remains to identify all cellular components involved in the organized hierarchy of heterogeneous cell populations within myeloma. LCR B cells are relatively rare populations that have been shown to grow colonies in CFC assays and that are chemoresistant, suggesting they potentially fit the cancer stem cell definition. Targeting clonotypic B-cell progenitors in addition to inducing apoptosis of terminally differentiated plasma cells by novel treatment strategies may reduce disease recurrence and may improve long-term survival rates in myeloma.
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